Patient willingness to undergo efavirenz dose reduction based on pharmacogenetic testing.
Among HIV-infected adults receiving efavirenz fixed-dose combination tablets, genotyping could guide efavirenz dose reduction but would require more pills. We assessed willingness to dose reduce among 129 patients at an HIV primary care clinic in the southeastern USA. When told that switching from one pill to two or three pills "might make you feel a little better", 47% expressed definite or possible willingness. This decreased to 9% if there was "a small chance it might not control your HIV as well". Clinical variables were not associated with willingness. Many patients receiving a fixed-dose combination tablet may be willing to take more pills in order to dose reduce, guided by genetic testing, but only if virologic control is not compromised.